G-protein-coupled receptors have a major role in transmembrane signalling in most eukaryotes and many are important drug targets. Here we report the 2.7 Å resolution crystal structure of a b 1 -adrenergic receptor in complex with the high-affinity antagonist cyanopindolol. The modified turkey (Meleagris gallopavo) receptor was selected to be in its antagonist conformation and its thermostability improved by earlier limited mutagenesis. The ligand-binding pocket comprises 15 side chains from amino acid residues in 4 transmembrane a-helices and extracellular loop 2. This loop defines the entrance of the ligand-binding pocket and is stabilized by two disulphide bonds and a sodium ion. Binding of cyanopindolol to the b 1 -adrenergic receptor and binding of carazolol to the b 2 -adrenergic receptor involve similar interactions. A short well-defined helix in cytoplasmic loop 2, not observed in either rhodopsin or the b 2 -adrenergic receptor, directly interacts by means of a tyrosine with the highly conserved DRY motif at the end of helix 3 that is essential for receptor activation.
G-protein-coupled receptors (GPCRs) are a large family of integral membrane proteins that are prevalent in eukaryotes from yeast to man, and function as key intermediaries in the transduction of signals from outside to inside the cell 1 . Activating molecules (agonists), such as hormones and neurotransmitters, bind to GPCRs from the extracellular side of the cell membrane and induce a large conformational change that propagates to the cytoplasmic surface 2, 3 , resulting in activation of G proteins and a consequent change in the level of intracellular messengers such as cAMP, Ca 21 or signalling lipids. There are over 800 different human GPCRs 4 , all of which share the characteristic arrangement of 7 transmembrane a-helices, with the polypeptide amino terminus on the extracellular side of the plasma membrane 5 . Analysis of the primary amino acid sequences of GPCRs has resulted in the definition of a number of families 6 , the largest of which, family A, includes the archetypal GPCR, rhodopsin. The three human b-adrenergic receptor (bAR) subtypes, b 1 , b 2 and b 3 , belong to family A and share 51% sequence identity between Trp 1.31 -Asp 5.73 and Glu 6.30 -Cys H8-Cterm ; that is, excluding the amino and carboxy termini and most of cytoplasmic loop 3 (Supplementary Fig. 1 ; superscripts refer to Ballesteros-Weinstein numbering 7 ). Drugs that inhibit b 1 and b 2 receptor signalling (antagonists and inverse agonists) are used to modulate heart function and are known as b-blockers 8 , but selective b 1 -antagonists are preferred because they have fewer side effects due to bronchial constriction by means of b 2 receptors in the lung. In contrast to the b 1 and b 2 receptors, the b 3 -adrenergic receptor (b 3 AR) is found in adipose tissue, where adrenaline stimulates metabolism, and is a potential target to treat obesity. Elucidation of the specificity determinants for drug affinity of the different bAR subtypes will allow the development of better subtypespecific b-blockers, with fewer side effects.
A milestone in the study of bARs was recently reached with the publication of a b 2 -adrenergic receptor (b 2 AR) structure in a complex with an antibody fragment, b 2 AR-Fab 9 , followed by the higher resolution structure of an engineered b 2 AR fused in the middle of the third cytoplasmic loop (CL3) to T4 lysozyme, b 2 AR-T4 (ref. 10 ).
These structures, both containing the high affinity antagonist carazolol, defined the overall architecture of b 2 AR and the structure of the ligand-binding pocket. However, the structures also raised questions of how a range of compounds can bind to the different but closely related bAR subtypes with different affinities. For example, the human b 1 and b 2 receptors are 67% identical within their transmembrane regions, but the residues that directly surround the ligandbinding pocket appear to be identical. Despite these similarities, larger antagonists such as CGP 20712A (see Supplementary Fig. 2 ) bind 500 times more strongly to b 1 AR than to b 2 AR, whereas ICI 118551 shows a 550-fold specificity for b 2 AR over b 1 AR 11 . There are also b 1 -and b 2 -specific agonists 12 . As an important step towards understanding subtype specificity, we have determined the structure of a b 1 -adrenergic receptor (b 1 AR).
Crystallization of b 1 AR GPCR crystallization is challenging, because GPCRs are usually unstable in detergent, contain unstructured regions and spontaneously cycle between an inactive antagonist state (R) and an active agonist state (R*), which may further decrease the stability 13 . The human b 1 AR is more difficult to purify than b 2 AR because it is very unstable in detergent. We therefore used turkey (M. gallopavo) b 1 AR, which is more stable than human b 1 AR 14 although less stable than human b 2 AR (M.J.S.-V. and C.G.T., unpublished observation). A mutated receptor, b 1 AR-m23, was constructed with enhanced thermostability over the wild-type receptor and an altered equilibrium between R and R* so that the mutant receptor was preferentially in the antagonist (R) state 15 . The receptor construct, b 1 AR36-m23 ( Fig. 1) , purified in octylthioglucoside and in the presence of cyanopindolol gave good crystals showing isotropic diffraction beyond 2.7 Å .
Pharmacological analysis of b 1 AR-m23
The mutant receptor b 1 AR-m23 bound the antagonists dihydroalprenolol and cyanopindolol with similar affinities to the wild-type receptor, but the agonists noradrenaline and isoprenaline bound more weakly by a factor of 2,470 and 650, respectively 15 . This reflects a change in the R to R* equilibrium of the receptor towards the antagonist R state. From this we predicted that, in a G-protein-coupling assay, the receptor would show no basal activity and that the concentration of agonist required for signalling would be orders of magnitude higher. Signalling assays were performed on stable cell lines expressing the wild-type b 1 AR truncated at the N and C termini (b 1 ARtrunc) and also containing the six thermostabilizing mutations (m23) (Supplementary Fig. 3 ). b 1 ARtrunc-m23 coupled efficiently to G proteins and elicited a robust stimulation of cAMP-responsive reporter gene, although the agonist concentration response curve, as expected, was shifted to the right 16 . The drug ICI 118551, an inverse agonist for both b 1 AR 17 and b 2 AR 18 , showed no reduction in the basal level of cAMP when added at a concentration 100-fold above its inhibition constant (K i ) to cells containing b 1 ARtruncm23, implying there is negligible basal constitutive activity. The structure we have determined contains the very high affinity antagonist cyanopindolol in the binding pocket and represents closely the inactive conformation with respect to G-protein coupling.
Overall structure and the extracellular loops The structure was solved by molecular replacement to 2.7 Å resolution with an R work of 0.212 and an R free of 0.268 (Supplementary Table 1 Supplementary Fig. 7) . Comparison of the structures of b 1 AR and b 2 AR reveals no evidence for any significant changes in backbone conformation at the sites of the six point mutants introduced 15 to stabilize b 1 AR. This is consistent with the observation that b 1 ARm23 binds antagonists with similar affinities to the wild-type receptor 15 and that it can couple efficiently to G proteins, although at higher agonist concentration (Supplementary Fig. 3 ). The basis for the thermostabilization by the six mutations R68 Supplementary Fig. 1 ). On the extracellular surface, a clear peak in the electron density is present at a position co-ordinated by the backbone carbonyl groups of residues Cys 192, Asp 195, Cys 198 and one or two water molecules ( Supplementary Fig. 8 ). This density was assigned to a sodium ion on the basis of its coordination geometry 20 . Its role, bound at the negative end of the EL2 a-helix dipole, may be to stabilize the helical conformation of EL2 and thus the structure of the entrance to the ligand-binding pocket. The large difference in EL2 conformation between the a-helix found in b 2 AR and the b-hairpin that closes off the retinal-binding site in rhodopsin is confirmed in the structure of b 1 AR, suggesting that the a-helix may be a common feature in those GPCRs that bind their ligands rapidly and reversibly.
Cytoplasmic loop structure
In all GPCRs, CL2 and CL3 are believed to have an important role in the binding, selectivity and activation of G proteins, CL2 being a, Diagram of the turkey b 1 AR sequence in relation to secondary structure elements. The residues in white circles indicate regions that are well ordered; the sequences in grey circles were not resolved in the structure. The sequences on an orange background were deleted to make the b 1 AR construct for expression. Thermostabilizing mutations are in red circles and two other mutations-C116L (increases functional expression) and C358A (eliminates palmitoylation site)-are in blue circles. The Na 1 ion is in purple. Numbers refer to the first and last amino acid residues in each helix (blue boxes), with the Ballesteros-Weinstein numbering in superscript. Helices were defined using the Kabsch and Sander algorithm 49 , with helix distortions being defined as residues that have main chain torsion angles that differ by more than 40u from standard a-helix values (260u,240u). b, Ribbon representation of the b 1 AR structure in rainbow colouration (N terminus, blue; C terminus, red), with the Na 1 ion in pink, the two near-by disulphide bonds in yellow, and cyanopindolol as a space-filling model. The extracellular loop 2 (EL2) and cytoplasmic loops 1 and 2 (CL1, CL2) are labelled.
important for the strength of the interaction and CL3 for specificity [21] [22] [23] [24] [25] . The b 1 AR and b 2 AR structures, along with rhodopsin 26 , have similar conformations for CL1, but there are major differences in CL2 and CL3. The CL3 differences are not of physiological relevance because they arise from deletions (b 1 AR), deletion and insertion of T4 lysozyme (b 2 AR-T4) or formation of an antibody complex (b 2 AR-Fab), with only the rhodopsin structure having a native CL3 (ref. 26 ). However, differences in the conformation of CL2 (Fig. 2) are important, because this region is very highly conserved between b 1 AR and b 2 AR, although poorly conserved with rhodopsin. In b 1 AR, CL2 forms a short a-helix (residues Pro 146 3.57 -Leu 152 3.63 ; Supplementary Fig. 9 ) parallel to the membrane surface whereas in both b 2 AR structures and in rhodopsin this loop is in an extended conformation (Fig. 2) . The a-helical conformation of CL2 observed in b 1 AR cannot be accommodated in either the b 2 AR-Fab complex 9 or the b 2 AR-T4 fusion 10 crystal structures because of lattice contacts with adjacent molecules. In b 1 AR, CL2 also makes lattice contacts, but these are different between each of the four molecules and it is therefore likely that the helical conformation found here represents the physiologically relevant structure for all bARs in the inactive conformation.
The CL2 loop has been proposed to function as the switch enabling G-protein activation 21 , and it is clear from the b 1 AR structure that this short a-helix interacts directly with the highly conserved Asp 138 3.49 Arg 139 3.50 Tyr 140 3.51 (DRY) motif in H3. Tyr 149 in CL2 is located sufficiently close to Asp 138 3.49 to allow the formation of a hydrogen bond (Fig. 2) between the tyrosine hydroxyl and the aspartate side chain. Supporting evidence for this structural role of Tyr 149 comes from the observation that the Y149A mutation makes b 1 AR less thermally stable (Supplementary Table 2 ). The equivalent Tyr 141 in both b 2 AR structures is in a cavity between H3, H4 and H6, but the biological relevance of this is unclear, owing to the perturbations in this region caused by either the T4 lysozyme fusion or by the bound antibody. Interestingly, a pattern of mutations consistent with an a-helical conformation for CL2 was found in the muscarinic M5 receptor, and the equivalent M5 mutation Y138A led to increased constitutive activity 21 .
A salt bridge between Arg 3.50 and Glu 6.30 , termed the 'ionic lock' (Fig. 2) , was proposed to have an essential role in maintaining GPCRs in an inactive state 27 but to break on receptor activation. Because the b 1 AR structure represents a receptor lacking basal activity and containing bound antagonist, it is highly likely to represent the R conformation. However, this salt bridge is not present in either the b 1 AR or the b 2 AR structures (Fig. 2) . This suggests that the ionic lock is not an essential feature of the inactive state. Even in dark-state rhodopsin, where these two charged residues are within hydrogen bonding distance 26, 28, 29 , the side chain B-factors of the two residues differ greatly (by 20-40 Å 2 ) 26 so there is no direct experimental evidence for any 'lock'. Supplementary Fig. 2 ) and both ligands bind with very high affinity to all bARs. Carazolol is present in the ligand-binding pocket of both b 2 structures, whereas the structure of b 1 contains cyanopindolol. In the b 1 AR structure there are 15 amino acid residues (using a 3.9 Å distance criterion) for which the side chains make contacts with cyanopindolol: 4 side chains are from H3, 3 are from H5, 4 are from H6, 2 are from H7 and 2 are from EL2 (Fig. 3) . All of these residues are identical to those in human b 2 AR, and the mode of binding of cyanopindolol to b 1 AR is, therefore, similar to that of carazolol in b 2 AR. However, the extra ring in the carazolol heterocyclic ring, owing to van der Waals contact with Tyr 199 5.38 in b 2 AR, pushes the ligand more deeply into the binding site. The nitrogen in the cyano-moiety of cyanopindolol makes a weak hydrogen bond with the hydroxyl of Thr 203 5.34 , which is located together with Phe201 5.32 on EL2 (Fig. 3) . The same hydrogen bonds between the ligand and Asp 121 3.32 , Asn 329 7.39 and Ser 211 5.42 are present in both b 1 AR and b 2 AR structures, but the side-chain rotamer conformation of Ser 211 5.42 is different (Fig. 4 and Methods).
Selectivity of the ligand-binding pocket
To explain why some ligands preferentially bind to either b 1 AR or b 2 AR, which is important in understanding the sub-type specificity of the human receptors 11 , there must be differences in amino acid residues close to the ligand-binding pocket that directly or indirectly affect binding. A comparison of residues within 8 Å of the binding pocket identified only two residues that are different between human b 1 AR and b 2 AR subtypes. The respective residues are Val 172 4 .56 and Phe 325 7.35 in b 1 AR, equivalent to Thr 164 4.56 and Tyr 308 7.35 in b 2 AR. These differences introduce polar residues near the binding pocket of b 2 AR relative to b 1 AR (Fig. 4) , which could affect ligand selectivity. Mutagenesis studies 30, 31 have also implied that Tyr 308 7.35 is important for agonist selectivity in b 2 AR. In b 2 AR, Tyr 308 7.35 is positioned close to the binding pocket and can form a hydrogen bond to Asn 293 6.55 . In b 1 AR the side chain of Asn 310 6.55 is closer to the cyano group of cyanopindolol and the equivalent residue, Phe 325 7.35 , is further from the binding pocket (Fig. 4) . As a result, there is no contact between Phe 325 7.35 in b 1 AR and cyanopindolol. Part of the ligand-binding site is formed by EL2, and the backbone positions within this highly structured region of b 1 AR differ from b 2 AR by an r.m.s.d. of only 0.84 Å , compared with 0.63 Å between the same residues in molecules A and B in the unit cell. There are also significant differences in the primary amino acid sequence in this region that change the shape and charge distribution around the entrance to the ligand-binding pocket ( Supplementary Fig. 10 , which is half of the putative ionic lock, is also shown as E247 in rhodopsin, and E285 and E268 in b 2 AR, respectively: E247 the sites of allosteric modulators 34 , and that the loop flexibility is important to the binding kinetics 35 . The structure of b 1 AR, when compared to that of b 2 AR, provides a sound basis for studying selectivity differences between bAR antagonists that are structurally similar to cyanopindolol and carazolol. However, many ligands, such as the inverse agonist CGP 20712A ( Supplementary Fig. 2 ), show very high selectivities 11 but are physically larger and structurally distinct from either cyanopindolol or carazolol. These ligands could well make contact with residues other than those described here.
Agonist binding and GPCR activation
The b 1 AR crystal structure shows the inactive state of the receptor, but it is notable that many agonists, including the natural ligands adrenaline and noradrenaline, are smaller than many of the best antagonists, including cyanopindolol. Agonists have a shorter distance, by two carbon-carbon bonds or 2-3 Å , between the catechol hydroxyl groups or their equivalent and the obligatory amine nitrogen. We superimposed (Fig. 4b) 5.46 , which are expected to hydrogen bond with the meta-and para-hydroxyl groups on the catechol ring [36] [37] [38] . As noticed previously 39 , the catechol hydroxyl groups are well spaced and well oriented to interact with the side chain hydroxyl groups of Ser 211 5.42 , Ser 212 5.43 and Ser 215 5.46 on H5, but cannot reach far enough to make good hydrogen bonds if the amine occupies the same position as it does adjacent to Asp 121 3.32 in the cyanopindolol complex, without a substantial structural change in the receptor. It seems very reasonable that the ligand-binding site in b 1 AR will contract by 2-3 Å on activation so that both ends of adrenaline can make good interactions with the residues on H3/H7 and H5. This view is also supported by engineered zinc-binding sites that activate the receptor 40, 41 . How this tightening around the ligand-binding site could propagate to the cytoplasmic surface and cause an outward 5-6 Å movement of H6 (refs 2, 3) is difficult to predict, because all the transmembrane helices except H1 and H3 have pronounced kinks at conserved proline residues, which means they could easily bend. However, one speculation is that the pulling of H5 towards the centre of the receptor on activation could force H3 and H6 apart, causing cytoplasmic loops CL2 and CL3 to move apart, as observed in photoactivated rhodopsin 3 , and trigger recruitment of the G-protein complex.
METHODS SUMMARY
Purification and crystallization. The b 1 AR construct T34-424/His 6 (see ref.
42) was the starting point for the generation of the b 1 AR36-m23 construct that crystallized. The C terminus was further truncated after Leu 367, and six histidines were added. Two segments, comprising residues 244-271 and 277-278 of CL3, were also deleted. The construct included the following eight point mutations: C116 3.27 L increased expression; C358A at the C terminus of H8 removed palmitoylation and helped crystallization; and R68 A and F338 7.48 M thermostabilized the receptor in the antagonist conformation 15 . The receptor was expressed using the baculovirus system and then purified 42 in decylmaltoside, with a detergent exchange to octylthioglucoside on the alprenolol sepharose column. Crystals were obtained by vapour diffusion at 18 uC with hanging drops after addition of an equal volume of reservoir solution (0.1 M N-(2-acetamido)iminodiacetic acid:NaOH, pH 6.9-7.3, and 29-32% PEG600) to purified receptor (6.0 mg ml
21
). Data collection, structure solution and refinement. Diffraction data were collected from many crystals on beamlines ID13 and ID23-2 at ESRF, Grenoble 43, 44 ; the data used for structure determination were collected at ID23-2 with a 10 mm beam using three positions on a single cryo-cooled crystal (100 K). Images were processed with MOSFLM and SCALA 45 . The structure was solved by molecular replacement with PHASER 46 , using the structure of human b 2 AR 10 as an initial model. All four copies of the molecule in the triclinic unit cell were located (Supplementary Figs 4 and 5) . The amino acid sequence was corrected, and the model refined with PHENIX 47 and rebuilt with O 48 (see Methods for further details). An overview of the B-factor distribution for b 1 AR molecules A and B is shown in Supplementary Fig. 6 . Figures were produced using Pymol (DeLano Scientific LLC).
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Purification and crystallization. Baculovirus expression in High 5 cells, membrane preparation, solubilization, IMAC and alprenolol sepharose chromatography were all performed as described previously 42 , except that solubilization and IMAC were performed in buffers containing the detergent decylmaltoside and the detergent was exchanged on the alprenolol sepharose column to octylthioglucoside; purified receptor was eluted from the alprenolol sepharose with cyanopindolol (30 mM). The buffer was exchanged to 10 mM Tris-HCl, pH 7.7, 50 mM NaCl, 0.1 mM EDTA, 0.35% octylthioglucoside and 0.5 mM cyanopindolol during concentration to give a final receptor concentration of 5.5-6.0 mg ml 21 . Using the thermally stabilized protein, a wide crystal screen was performed in four different detergents. A total of 58 mg of receptor was used to set up 17,800 crystallization trials in an MRC ultraviolet transparent crystallization plate and imaged with the MRC multiwavelength imaging system at 380 nm. Promising looking crystals were then imaged at 280 nm to exclude salt and detergent crystals. The receptor crystallization in octylthioglucoside was optimised by vapour diffusion at 18 uC with hanging drops after addition of an equal volume of reservoir solution (0.1 M ADA, pH 6.9-7.3, and 29-32% PEG 600). Crystals were mounted on Hampton CrystalCap HT loops and were cryo-cooled in liquid nitrogen. Cryoprotection of crystals was achieved by increasing the PEG 600 concentration in the drop to 55-70%. Data collection, structure solution and refinement. The first diffraction patterns from microcrystals grown in the primary crystallization screens were tested with a 5 mm beam on beamline ID13 (ref. 43 ) at the European Synchrotron Radiation Facility, Grenoble. The best crystallization conditions were refined to improve diffraction quality and the optimized crystals were then screened at ID23-2 with a 10 mm focused beam; the micro-beams helped to deal with heterogeneous diffraction within a single crystal. Diffraction data were collected with a Mar 225 CCD detector on the microfocus beamline ID23-2 (wavelength, 0.8726 Å ) using three positions on a single cryo-cooled crystal (100 K) with dimensions 240 3 40 3 10 mm. The cyanopindolol ligand, detergent, water molecules and sodium ions were added at a late stage of refinement. Non-crystallographic restraints were not applied to detergent and water molecules. The correct side-chain rotamer of Ser 211 was ambiguous with both gauche 1 and trans rotamers giving an equally good fit to the electron density after refinement. The gauche 1 conformation was chosen because the trans conformation resulted in a short contact of 2.8 Å between the b-carbon of Ser 211 and the carbonyl oxygen of residue 207. In addition, the gauche 1 conformation allows the serine hydroxyl to act as both a hydrogen bond donor and an acceptor, whereas it can only act as an acceptor in the trans conformation. An overview of the B-factor distribution for b 1 AR molecules A and B is shown in Supplementary Fig. 6 , alongside rhodopsin (PDB code 1GZM) and b 2 AR-T4 (PDB code 2RH1). G-protein-coupling assays and cAMP measurement. Stable cell lines expressing the bAR-m23 mutation were made. A stable clonal CHO-K1 cell line expressing a CRE-SPAP reporter gene (six cAMP response elements (CRE) upstream of a secreted placental alkaline phosphatase (SPAP) gene) was transfected with plasmid pcDNA3 containing the bAR-m23 complementary DNA. The transfected cells were selected by neomycin resistance (1 mg ml 21 ; for the turkey receptor) and hygromycin resistance (200 mg ml
21
; for the CRE-SPAP reporter gene) for three weeks, and then single clones were isolated by dilution cloning to give clonal lines (CHO-m23-SPAP cells).
Whole-cell binding assays using 3 H-CGP12177 were performed and the K i values of available agonists and antagonists were determined from competition curves (J.G.B., unpublished observation). The ability of bAR-m23 to couple to G proteins was assessed by using a CRE-SPAP reporter assay as described previously 50 . In brief, confluent cells in serum-free medium were incubated for 5 h with the agonist, or after pre-treatment with antagonist for 1 h. Cells were then incubated for a further hour in the absence of ligands and the level of secreted alkaline phosphates then determined by a colorimetric reaction using pNPP. To determine what conformation bAR-m23 has in the absence of ligand, the effect of a known inverse agonist ICI 118551 was tested on the CHO-m23-SPAP cells. Confluent cells were pre-labelled with 3 H-adenine in serum-free medium for 2 h, were removed and then the cells were incubated in 100 mM isobutylmethylxanthine (IBMX, a non-specific phosphodiesterase inhibitor) and ICI 118551. After 5 h the reaction was terminated and 3 H-cAMP separated from other 3 Hnucleotides by sequential Dowex and alumina column chromatography, as described previously 51 . Under these conditions any inverse agonist affects of ICI 118551 would have been seen 52 . Data for all experiments were analysed by GraphPad Prism; all data are presented as mean 6 s.e.m. of triplicate determinations, where n is the number of separate experiments. Using the same assay, cyanopindolol appeared to be a very weak partial agonist.
All agonist ligands used were examined in the parent CHO-SPAP cells (that is, cells expressing the reporter but not bAR-m23); no effects were seen in response to any of the ligands over a 10 7 concentration range despite an increase in CRE-SPAP production in response to 3 mM forskolin. This suggests that all the responses in CHO-m23-SPAP cells were indeed occurring by means of bAR-m23. 
